Drug Interactions between Benylin Multi-Symptom and methoxyflurane
This report displays the potential drug interactions for the following 2 drugs:
- Benylin Multi-Symptom (diphenhydramine/pseudoephedrine)
- methoxyflurane
Interactions between your drugs
methoxyflurane pseudoephedrine
Applies to: methoxyflurane and Benylin Multi-Symptom (diphenhydramine / pseudoephedrine)
GENERALLY AVOID: The administration of volatile general anesthetics during therapy with indirect-acting sympathomimetics (e.g. methylphenidate, ephedrine) or their derivatives may increase the risk of hypertension and/or cardiac arrhythmias. The proposed mechanism is anesthetic-induced myocardial sensitization to the stimulation caused by sympathomimetics.
MANAGEMENT: Until more information is available, caution is advisable if volatile general anesthetics are administered concomitantly with indirect-acting sympathomimetics or any of their derivatives. If the combination is required, dosage adjustments are recommended, and the patient's hemodynamic status should be closely monitored. When surgery is planned, it is recommended that indirect-acting sympathomimetics or their derivatives be discontinued prior to the day of surgery. Prescribing information for individual products should be consulted.
References (8)
- (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
- (2022) "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc
- (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2013) "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical
- (2021) "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.
- (2019) "Product Information. Isoflurane (isoflurane)." Piramal Critical Care Ltd
Drug and food interactions
diphenhydrAMINE food
Applies to: Benylin Multi-Symptom (diphenhydramine / pseudoephedrine)
GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.
MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
References (1)
- Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12
methoxyflurane food
Applies to: methoxyflurane
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents. Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (5)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
pseudoephedrine food
Applies to: Benylin Multi-Symptom (diphenhydramine / pseudoephedrine)
MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.
MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.
References (7)
- Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
- Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
- (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
- (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
- (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
- (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
- (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.